{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-091966","form_type":"8-K","ticker":"ONCO","cik":"0001782107","company_name":"Onconetix, Inc.","filed_at":"2025-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.971982+00:00","generated_at":"2026-05-17T05:35:23.302616+00:00","sec_items":["1.01","1.02","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Onconetix raises $12.9M via Series D convertible preferred stock and warrants in PIPE financing","bullets":["Company sold 16,099 shares of Series D convertible preferred stock and warrants to purchase 4,362,827 shares of common stock to eleven institutional investors.","Aggregate purchase price of approximately $12.9 million, with about $9.3 million in cash and the balance offsetting amounts owed to Veru Inc. and others.","Series D preferred stock has a stated value of $1,000 per share, convertible into common stock at an initial conversion price of $3.6896 per share.","Company entered into a registration rights agreement with the PIPE investors for resale of underlying common shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-091966","json":"https://secwatch.observer/filing/0001213900-25-091966.json","markdown":"https://secwatch.observer/filing/0001213900-25-091966.md","text":"https://secwatch.observer/filing/0001213900-25-091966.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025091966/0001213900-25-091966-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025091966/ea0258830-8k_onconetix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T05:35:23.302616+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"36757545cbc78a1f86ae0504a0f3c9e445c43025","claim":"Onconetix, Inc. issued warrants to purchase 4,362,827 shares of Common Stock of warrant to eleven institutional investors for included in aggregate purchase price of approximately $12.9 million.","evidence_excerpt":"On September 22, 2025, Onconetix, Inc., a Delaware corporation (the “ Company ”), entered into, and sold to eleven institutional investor(s) (collectively, the “ PIPE Investors ”), pursuant to a securities purchase agreement (the “ Securities Purchase Agreement ”) an aggregate of 16,099 shares of Series D convertible preferred stock, par value $0.00001 per share (“ Series D Preferred Stock ”), which are convertible into common stock of the Company, $0.00001 par value per share (the “ Common Stock ”), which includes an issuance of 500 shares of Series D Preferred Stock to a certain investor as consideration for the PIPE Investors’ irrevocable commitment to purchase shares of the Series D Preferred Stock, and warrants to purchase 4,362,827 shares of Common Stock (the “ Warrants ” and, together with the Series D Preferred Stock, the “ PIPE Securities ”), for an aggregate purchase price of approximately $12.9 million.","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025091966/0001213900-25-091966-index.htm","confidence":0.98,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"warrants to purchase 4,362,827 shares of Common Stock"},{"label":"Purchaser","value":"eleven institutional investors"},{"label":"Consideration","value":"included in aggregate purchase price of approximately $12.9 million"}],"fact_type":"equity_issuance"},{"claim_id":"5a7ae56c546fd95acdf972a67614b3ae0b38c4da","claim":"Onconetix, Inc. issued 16,099 shares of Series D convertible preferred stock of preferred stock to eleven institutional investors for aggregate purchase price of approximately $12.9 million of which approximately $9.3 million was paid in cash and the balance was used to offset certain amounts.","evidence_excerpt":"On September 22, 2025, Onconetix, Inc., a Delaware corporation (the “ Company ”), entered into, and sold to eleven institutional investor(s) (collectively, the “ PIPE Investors ”), pursuant to a securities purchase agreement (the “ Securities Purchase Agreement ”) an aggregate of 16,099 shares of Series D convertible preferred stock, par value $0.00001 per share (“ Series D Preferred Stock ”), which are convertible into common stock of the Company, $0.00001 par value per share (the “ Common Stock ”), which includes an issuance of 500 shares of Series D Preferred Stock to a certain investor as consideration for the PIPE Investors’ irrevocable commitment to purchase shares of the Series D Preferred Stock, and warrants to purchase 4,362,827 shares of Common Stock (the “ Warrants ” and, together with the Series D Preferred Stock, the “ PIPE Securities ”), for an aggregate purchase price of approximately $12.9 million.","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025091966/0001213900-25-091966-index.htm","confidence":0.98,"family_label":"Equity Issuances","details":[{"label":"Security","value":"preferred stock"},{"label":"Shares","value":"16,099 shares of Series D convertible preferred stock"},{"label":"Purchaser","value":"eleven institutional investors"},{"label":"Consideration","value":"aggregate purchase price of approximately $12.9 million of which approximately $9.3 million was paid in cash and the balance was used to offset certain amounts"}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}